Abstract: This paper summarizes the current situation and existing problems of China′s innovative drug market access policy from the basic aspects of innovative drug market access, such as intellectual property rights, drug pricing, medical insurance and bidding procurement. Based on the comprehensive analysis of Japan′s innovative drug market access policy, through the comprehensive comparison of the two countries innovative drug market access policy differences, the paper put forward the practical measures to encourage the listing of innovative drugs in China, from the intellectual property rights, drug pricing, medical security and tender procurement in four areas.